Company profile for ContraFect Corporation

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of ...
ContraFect is a clinical-stage biotechnology company focused on discovering and developing biologic therapies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. We intend to address life threatening infections using our therapeutic product candidates from our platform of direct lytic agents (DLAs), which include lysins and amurin peptides.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
28 Wells Ave Yonkers, NY 10701 (914) 207-2300
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com//news-release/2023/10/16/2760540/0/en/ContraFect-Announces-FDA-Clearance-of-CF-370-IND-Application-to-Proceed-With-Phase-1-Clinical-Study.html

GLOBENEWSWIRE
16 Oct 2023

https://www.globenewswire.com//news-release/2023/09/19/2745601/0/en/ContraFect-to-Present-at-the-ASM-ESCMID-Joint-Conference-on-Drug-Development.html

GLOBENEWSWIRE
19 Sep 2023

https://www.globenewswire.com//news-release/2023/09/18/2744662/0/en/ContraFect-Announces-Submission-of-IND-Application-to-the-FDA-for-its-Development-Candidate-CF-370.html

GLOBENEWSWIRE
18 Sep 2023

https://www.globenewswire.com/news-release/2023/08/28/2732525/0/en/ContraFect-to-Present-at-the-World-Anti-Microbial-Resistance-Congress-2023.html

GLOBENEWSWIRE
28 Aug 2023

https://www.globenewswire.com/news-release/2023/06/27/2695308/0/en/ContraFect-Enters-Into-a-Warrant-Exercise-Transaction-for-Proceeds-of-9-6-Million.html

GLOBENEWSWIRE
27 Jun 2023

https://www.globenewswire.com/news-release/2023/06/20/2691115/0/en/ContraFect-Data-Presentations-at-ASM-Microbe-2023-Demonstrate-the-Power-of-the-Company-s-Proprietary-Platform-to-Discover-New-Agents-Targeting-Antibiotic-Resistant-Gram-negative-Pa.html

GLOBENEWSWIRE
20 Jun 2023

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty